[{"id":"52a20f08-fb55-44a8-b556-28ccbdd505e2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05421663","created_at":"2022-06-16T15:00:08.321Z","updated_at":"2025-02-25T16:39:05.573Z","phase":"Phase 1","brief_title":"A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","source_id_and_acronym":"NCT05421663","lead_sponsor":"Janssen Research \u0026 Development, LLC","biomarkers":" CD20","pipe":" | ","alterations":" CD20 positive","tags":["CD20"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prizloncabtagene autoleucel (JNJ-4496)"],"overall_status":"Recruiting","enrollment":" Enrollment 230","initiation":"Initiation: 08/12/2022","start_date":" 08/12/2022","primary_txt":" Primary completion: 05/29/2026","primary_completion_date":" 05/29/2026","study_txt":" Completion: 12/29/2028","study_completion_date":" 12/29/2028","last_update_posted":"2025-02-06"},{"id":"1d005789-e79e-4054-b5fd-335dbb773cc6","acronym":"ELEVATION","url":"https://clinicaltrials.gov/study/NCT05800977","created_at":"2023-04-06T14:03:13.007Z","updated_at":"2024-07-02T16:35:51.284Z","phase":"Phase 1b/2","brief_title":"A Study of C-CAR039 (Prizloncabtagene Autoleucel) in Patients With Relapsed/Refractory Large B-Cell Lymphoma","source_id_and_acronym":"NCT05800977 - ELEVATION","lead_sponsor":"Cellular Biomedicine Group Ltd.","biomarkers":" BCL2 • CD20 • CD19 • BCL6","pipe":" | ","alterations":" CD20 positive • CD20 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement","tags":["BCL2 • CD20 • CD19 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive • CD20 expression • CD19 expression • BCL6 rearrangement • BCL2 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prizloncabtagene autoleucel (JNJ-4496)"],"overall_status":"Recruiting","enrollment":" Enrollment 72","initiation":"Initiation: 02/22/2023","start_date":" 02/22/2023","primary_txt":" Primary completion: 03/31/2027","primary_completion_date":" 03/31/2027","study_txt":" Completion: 03/31/2027","study_completion_date":" 03/31/2027","last_update_posted":"2023-04-06"},{"id":"f1c100e7-8d04-4bec-a1f7-437ff514eda2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05149391","created_at":"2021-12-08T12:53:38.257Z","updated_at":"2024-07-02T16:36:19.734Z","phase":"Phase 1","brief_title":"A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma","source_id_and_acronym":"NCT05149391","lead_sponsor":"Peking University","biomarkers":" BCL2 • BCL6","pipe":" | ","alterations":" CD20 positive","tags":["BCL2 • BCL6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD20 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e prizloncabtagene autoleucel (JNJ-4496)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/20/2021","start_date":" 07/20/2021","primary_txt":" Primary completion: 07/01/2024","primary_completion_date":" 07/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2021-12-08"}]